Tag Archives: FierceBiotech

Apitope moves Graves’ disease candidate toward Phase 2; a primer on autoimmune disease “for people in a hurry.”

The News: Apitope International NV has taken a step closer to developing the first new treatment option in decades for thyroid disorder Graves’ disease after posting positive results in a… Read more »

Biotech IPOs rock in 2018. More are storming into the queue.

Steve’s Take: Cutting-edge biotech startups and more established privately-funded but publicly held hopefuls are far and away the winners of the race for deep-pocket investors since New Year’s. I thought… Read more »

Akebia surges on anemia drug deal; is a much bigger breakout looming?

The News: Akebia Therapeutics Inc. (Cambridge MA) leaped 18% Tuesday (May 16, 2017) sparked by news the fledgling dialysis treatment developer and Swiss backer Vifor Pharma Group Ltd. (Glattburg) agreed… Read more »

Arrowhead Pharma obliterated after ditching Hep B candidate; oh, that’s right, biotechs are risky

Shares of Arrowhead Pharmaceuticals Inc. (Pasadena CA) cratered 69% to $1.44 last week (November 28 to December 2, 2016) after the company said it would stop developing all drugs being… Read more »

Study Suggests Revolutionary Drug Could Benefit Patients with Early Stage Alzheimer’s

A trial of a new Alzheimer’s drug has shown it could benefit patients in the earliest stages of the disease, raising hopes that a treatment for the devastating condition may… Read more »